OPUS IP
      
 
  • Home
  • ABOUT OPUS IP
  • PROTECTION
  • IP OFFICES
  • UKIPO
  • NEWS/UPDATES
  • RECENT HEARINGS
  • PATENTS
  • TRADEMARKS
  • DESIGNS
  • UK IPEC DECISIONS
  • EPO
  • NEWS/UPDATES
  • APPEAL DECISIONS
  • G/XX DECISIONS 2010-2019
  • G/XX DECISIONS 2000-2009
  • G/XX DECISIONS 1990-2000
  • G/XX DECISIONS PRE-1990
  • J/XX APPEALS 2010-2019
  • J/XX APPEALS 2000-2009
  • J/XX APPEALS 1990-2000
  • J/XX APPEALS PRE-1990
  • T/XXXX APPEALS 2010-2019
  • T/XXXX APPEALS 2000-2009
  • T/XXXX APPEALS 1990-1999
  • T/XXXX APPEALS pre-1990
  • WIPO – PCT/MADRID/HAGUE
  • NEWS/UPDATES
  • PCT NEWSLETTER
  • PATENTS NEWS
  • TREATY MODIFICATIONS
  • MADRID SYSTEM (TM)
  • HAGUE SYSTEM (DESIGNS)
  • PATENTSCOPE/SEARCHING
  • USPTO
  • NEWS/UPDATES
  • GENERAL
  • PATENTS
  • TRADEMARKS
  • COPYRIGHT
  • EUIPO
  • NEWS/UPDATES
  • SEARCH CASES (EXTERNAL)
  • IP NEWS/LINKS
  • LINKS TO IP RESOURCES
  • SITE
  • LOG-IN
 

HHS nominee Azar declines to comment on Allergan patent move

29th November 2017

  1. HHS nominee Azar declines to comment on Allergan patent move  Reuters
  2. Azar Opposes Abuse Of Drug Patents, REMS & Gag Orders; Open To Designing Part B Like Part D  Inside Health Policy
  3. Full coverage

 
 
 
 

OPUS IP on X (formerly Twitter)…

Twitter feed is not available at the moment.
 
 
 

RSS RECENT PATENT NEWS…

  • Sony Has Thrown In The Virtual Towel By Selling VR Patents To Meta - OpenCritic
  • Key Takeaways: Navigating Follow-On Patents in Bio-Pharma - JDSupra
  • Dutch court bars Merck's Keytruda SC in eight European markets in Halozyme patent case - The Pharma Letter
  • Sony Potentially Moving On From VR With Patents Being Sold - Cinelinx
 
 

RSS UK BUSINESS NEWS…

  • OpenAI says teen ChatGPT use limited but research finds it an 'unacceptable risk'
  • Boots sold in £7bn deal to Canadian billionaire family
  • No child should have to learn in a cold classroom - children's commissioner
  • Ex-bankers jailed for rigging rates have convictions quashed
 
 
 

Designed by Industrial Action

Copyright © 2026 OPUS IP Limited. All Rights Reserved

OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION